Fondazione Tettamanti, Formula Pharmaceuticals deal

Fondazione Tettamanti granted Formula exclusive, worldwide rights to develop and commercialize C.I.K. CAR, an allogeneic, non-viral chimeric antigen receptor (CAR) technology that uses cytokine-induce...